Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) securities between November 25, 2019 and May 3, 2021.
ChemoCentryx investors may receive additional information about this investigation by clicking the link "Submit Your Information" above.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.
On May 4, 2021, the U.S. Food and Drug Administration (“FDA”) released a “Briefing Document” concerning ChemoCentryx’s drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody vasculitis. In the Briefing Document, the FDA stated, “[a]lthough primary efficacy comparisons were statistically significant, the review team has identified several areas of concern, raising uncertainties about the interpretability of the[] data and the clinical meaningfulness of the[] results.”
Following this news, ChemoCentryx’s stock price is down approximately 45% during intraday trading on May 4, 2021.
If you wish to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.